title: Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.
abstract: Fabry disease is a multisystem, X-linked, lysosomal storage disorder caused by a mutation in the GLA gene on chromosome Xq22 resulting in alpha-galactosidase A enzyme (α-Gal A) deficiency. Neurological manifestations other than cerebrovascular accidents include small fibre neuropathy and dysautonomic disorders, which may be the presenting clinical features in a proportion of patients. An atypical disease onset may be misdiagnosed until the emergence of a more typical clinical picture, characterized by chronic renal and cardiac failure. Thus, neurologists should consider Fabry disease in differential diagnosis and provide an appropriate diagnostic work up. This review focuses on central and peripheral nervous system involving available diagnostic tools and diagnostic work up in Fabry disease. It also covers the most recent evidence regarding enzyme replacement therapy.
authors.affiliation: Department of Emergency Neurology, IRCCS C. Mondino National Institute of Neurology Foundation, Pavia, Italy. anna.bersano@gmail.com
authors.forename: A
authors.initials: A
authors.lastname: Bersano
authors.forename: S
authors.initials: S
authors.lastname: Lanfranconi
authors.forename: C
authors.initials: C
authors.lastname: Valcarenghi
authors.forename: N
authors.initials: N
authors.lastname: Bresolin
authors.forename: G
authors.initials: G
authors.lastname: Micieli
authors.forename: P
authors.initials: P
authors.lastname: Baron
mesh_terms: D002561:Cerebrovascular Disorders / Q000175:diagnosis / Q000209:etiology; D003937:Diagnosis, Differential; D056947:Enzyme Replacement Therapy; D000795:Fabry Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology*; D006801:Humans; D010523:Peripheral Nervous System Diseases / Q000175:diagnosis / Q000209:etiology; D000519:alpha-Galactosidase / Q000627:therapeutic use*
chemical_list: D000519:alpha-Galactosidase